Related Experiment Video
Updated: Aug 14, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic
Simone C Sorkin1, Francisco J Forestiero, Mario H Hirata
1Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, Brazil.
Apolipoprotein A-I (APOA1) gene variants influence triglyceride levels and response to atorvastatin, particularly in hypercholesterolemic men and women. These APOA1 polymorphisms impact baseline lipid concentrations and treatment outcomes.
Area of Science:
- Genetics and Molecular Biology
- Cardiovascular Disease Research
- Pharmacogenomics
Background:
- Apolipoprotein A-I (APOA1) gene polymorphisms are linked to variations in low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels.
- The association of common APOA1 variants with baseline triglyceride levels and atorvastatin response in hypercholesterolemia requires further investigation.
Purpose of the Study:
- To investigate the association between APOA1 common variants and serum triglyceride concentrations.
- To evaluate the impact of APOA1 polymorphisms on the response to atorvastatin treatment in hypercholesterolemic individuals.
Main Methods:
- Evaluated APOA1 G-75A and C83T polymorphisms in 150 hypercholesterolemic (HC) and 93 normolipidemic (NL) Brazilian individuals.
- Analyzed serum lipids and APOA1 polymorphisms using polymerase chain reaction and restriction fragment length polymorphism after 4 weeks of atorvastatin treatment (10 mg/day).
Main Results:
- The APOA1 G-75A polymorphism correlated with differences in triglyceride and very low-density lipoprotein (VLDL)-cholesterol serum concentrations in HC men (p=0.026).
- Women with the GG/CC haplotype showed reduced triglyceride and VLDL-cholesterol post-atorvastatin treatment (p=0.020).
- Men carrying the GG/CC haplotype exhibited a trend towards a slightly lower reduction in serum triglyceride levels with atorvastatin (p=0.051).
Conclusions:
- APOA1 polymorphisms are associated with baseline serum triglyceride and VLDL-cholesterol levels.
- The response to atorvastatin treatment concerning triglyceride and VLDL-cholesterol variations is gender-specific and influenced by APOA1 polymorphisms.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Pharmacogenomics: Identification of New Drug Targets
Principles of Pharmacogenetics: Types of Genetic Variants
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
